Second-Line and Third-Line Treatment Options for Metastatic HER2+ Breast Cancer

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

Survivors of breast cancer face increased cardiovascular risks due to treatment-related cardiotoxicity, and understanding these risks is crucial for effective management and prevention.